Back

Levosimendan use in anthracycline-induced cardiomyopathy: reversing the irreversible ?

12 May 2024 (15:18 - 15:27)
Organised by: Logo
Congress Presentation Part of: Cardio-oncology 3 Cardio-Oncology HFA Premium Access Heart Failure 2024 Heart Failure Association (HFA)

About the speaker

Photo
Doctor Vasiliki Tassi

Evangelismos Hospital, Athens (Greece)

4 More presentations in this session

Presentation thumbnail
Cardiotoxicity due to combined target therapy of malignant melanoma with full recovery after its discontinuation
Doctor V. Dimitrova (Sofia, BG)
Slides Video
Presentation thumbnail
Multidisciplinary approach in cardio-oncology: putting words into action
Doctor A. Pons Riverola (Barcelona, ES)
Slides Video
Presentation thumbnail
Immune checkpoint inhibitor-associated myocarditis: a rare presentation with electrical storm in a young patient with Hodgkin lymphoma
Doctor A. Stavrati (Thessaloniki, GR)
Slides Video
Presentation thumbnail
Anthracycline chemotherapy-related cardiac dysfunction? It is not always what it seems
Doctor S. Jimenez-Marrero (Barcelona, ES) Doctor H. Morillas Climent (Barcelona, ES)
Slides Video

Access the full session

Session thumbnail
Cardio-oncology 3

The Event

Event poster

Heart Failure 2024

12 May 2024 15:18 CET
You may be interested in
thumbnail
Congress Presentation
Doxorubicin-induced ventricular arrhythmias and cardiomyopathy - complete recovery with drug therapy
thumbnail
Congress Presentation
When does watchful waiting stop for cancer patients?: a cardiologist's perspective
thumbnail
Congress Session
Cardio-oncology in practice: managing cancer therapy–related cardiac disease

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources